Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Eiger BioPharmaceuticals

Nasdaq:EIGR
Snowflake Description

Adequate balance sheet with moderate growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
EIGR
Nasdaq
$171M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Eiger BioPharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare diseases in the United States and internationally. The last earnings update was 15 days ago. More info.


Add to Portfolio Compare Print
  • Eiger BioPharmaceuticals has significant price volatility in the past 3 months.
EIGR Share Price and Events
7 Day Returns
24.9%
NasdaqGM:EIGR
5.2%
US Biotechs
10.5%
US Market
1 Year Returns
-50.1%
NasdaqGM:EIGR
0%
US Biotechs
-11.5%
US Market
EIGR Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Eiger BioPharmaceuticals (EIGR) 24.9% -29.9% -54.7% -50.1% -39% -
US Biotechs 5.2% -6.5% -8.7% 0% 6.2% -10.4%
US Market 10.5% -15.4% -21.4% -11.5% 5.4% 18.1%
1 Year Return vs Industry and Market
  • EIGR underperformed the Biotechs industry which returned 0% over the past year.
  • EIGR underperformed the Market in United States of America which returned -11.5% over the past year.
Price Volatility
EIGR
Industry
5yr Volatility vs Market
Related Companies

EIGR Value

 Is Eiger BioPharmaceuticals undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Eiger BioPharmaceuticals. This is due to cash flow or dividend data being unavailable. The share price is $6.98.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Eiger BioPharmaceuticals's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Eiger BioPharmaceuticals's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGM:EIGR PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $-3.08
NasdaqGM:EIGR Share Price ** NasdaqGM (2020-03-27) in USD $6.98
United States of America Biotechs Industry PE Ratio Median Figure of 37 Publicly-Listed Biotechs Companies 15.4x
United States of America Market PE Ratio Median Figure of 2,939 Publicly-Listed Companies 12.96x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Eiger BioPharmaceuticals.

NasdaqGM:EIGR PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:EIGR Share Price ÷ EPS (both in USD)

= 6.98 ÷ -3.08

-2.26x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Eiger BioPharmaceuticals is loss making, we can't compare its value to the US Biotechs industry average.
  • Eiger BioPharmaceuticals is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Eiger BioPharmaceuticals's expected growth come at a high price?
Raw Data
NasdaqGM:EIGR PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -2.26x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts
52.6%per year
United States of America Biotechs Industry PEG Ratio Median Figure of 34 Publicly-Listed Biotechs Companies 0.96x
United States of America Market PEG Ratio Median Figure of 2,005 Publicly-Listed Companies 1x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Eiger BioPharmaceuticals, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Eiger BioPharmaceuticals's assets?
Raw Data
NasdaqGM:EIGR PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $2.30
NasdaqGM:EIGR Share Price * NasdaqGM (2020-03-27) in USD $6.98
United States of America Biotechs Industry PB Ratio Median Figure of 429 Publicly-Listed Biotechs Companies 2.53x
United States of America Market PB Ratio Median Figure of 5,148 Publicly-Listed Companies 1.26x
NasdaqGM:EIGR PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:EIGR Share Price ÷ Book Value per Share (both in USD)

= 6.98 ÷ 2.30

3.03x

* Primary Listing of Eiger BioPharmaceuticals.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Eiger BioPharmaceuticals is overvalued based on assets compared to the US Biotechs industry average.
X
Value checks
We assess Eiger BioPharmaceuticals's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Eiger BioPharmaceuticals has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

EIGR Future Performance

 How is Eiger BioPharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 4 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
52.6%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Eiger BioPharmaceuticals expected to grow at an attractive rate?
  • Eiger BioPharmaceuticals's earnings growth is expected to exceed the low risk savings rate of 1.7%.
Growth vs Market Checks
  • Eiger BioPharmaceuticals's earnings growth is expected to exceed the United States of America market average.
  • Unable to compare Eiger BioPharmaceuticals's revenue growth to the United States of America market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
NasdaqGM:EIGR Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGM:EIGR Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts 52.6%
United States of America Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 18.6%
United States of America Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 15.7%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 12.3%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGM:EIGR Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGM:EIGR Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 304 88 3
2023-12-31 198 68 4
2022-12-31 71 -38 4
2021-12-31 52 -57 4
2020-12-31 4 5 -66 3
2020-03-28
NasdaqGM:EIGR Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 -64 -70
2019-09-30 -61 -70
2019-06-30 -60 -68
2019-03-31 -53 -61
2018-12-31 -43 -52
2018-09-30 -41 -47
2018-06-30 -35 -39
2018-03-31 -36 -40
2017-12-31 -38 -42
2017-09-30 -39 -44
2017-06-30 -38 -47
2017-03-31 -45 -49

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Eiger BioPharmaceuticals's earnings are expected to grow significantly at over 20% yearly.
  • Unable to determine if Eiger BioPharmaceuticals is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGM:EIGR Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below

All data from Eiger BioPharmaceuticals Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:EIGR Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31 2.39 4.29 0.49 3.00
2023-12-31 1.90 7.38 -0.55 4.00
2022-12-31 -0.96 0.89 -2.03 4.00
2021-12-31 -1.70 -0.90 -2.75 4.00
2020-12-31 -2.12 -1.06 -2.83 3.00
2020-03-28
NasdaqGM:EIGR Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 -3.08
2019-09-30 -3.30
2019-06-30 -3.65
2019-03-31 -3.83
2018-12-31 -3.84
2018-09-30 -4.01
2018-06-30 -3.81
2018-03-31 -4.32
2017-12-31 -4.86
2017-09-30 -5.30
2017-06-30 -5.68
2017-03-31 -6.18

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Eiger BioPharmaceuticals will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Eiger BioPharmaceuticals's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Eiger BioPharmaceuticals has a total score of 3/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

EIGR Past Performance

  How has Eiger BioPharmaceuticals performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Eiger BioPharmaceuticals's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Eiger BioPharmaceuticals does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Eiger BioPharmaceuticals's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Eiger BioPharmaceuticals's 1-year growth to the US Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Eiger BioPharmaceuticals's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Eiger BioPharmaceuticals Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:EIGR Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 -70.25 17.11 50.79
2019-09-30 -69.83 16.61 51.87
2019-06-30 -68.36 16.01 51.01
2019-03-31 -60.75 15.02 44.45
2018-12-31 -52.39 13.96 37.09
2018-09-30 -46.78 12.68 32.86
2018-06-30 -38.81 11.76 25.81
2018-03-31 -40.04 11.47 27.57
2017-12-31 -42.45 12.00 29.52
2017-09-30 -44.32 12.73 31.12
2017-06-30 -46.52 13.26 33.04
2017-03-31 -48.58 12.80 35.63
2016-12-31 -47.09 13.11 33.01
2016-09-30 -41.38 12.66 27.26
2016-06-30 -32.88 10.16 21.30
2016-03-31 -22.27 8.26 12.59
2015-12-31 -13.32 4.86 8.12
2015-09-30 -7.05 2.24 4.82
2014-12-31 -1.52 0.87 0.64
2013-12-31 -0.95 0.53 0.43

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Eiger BioPharmaceuticals has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Eiger BioPharmaceuticals has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Eiger BioPharmaceuticals improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Eiger BioPharmaceuticals's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Eiger BioPharmaceuticals has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

EIGR Health

 How is Eiger BioPharmaceuticals's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Eiger BioPharmaceuticals's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Eiger BioPharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Eiger BioPharmaceuticals's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Eiger BioPharmaceuticals's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 3.3x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Eiger BioPharmaceuticals Company Filings, last reported 2 months ago.

NasdaqGM:EIGR Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 56.48 30.39 94.99
2019-09-30 71.66 30.20 109.95
2019-06-30 88.08 30.02 125.34
2019-03-31 50.81 29.84 85.79
2018-12-31 66.59 25.62 100.35
2018-09-30 33.77 25.42 64.94
2018-06-30 49.28 20.27 73.49
2018-03-31 14.73 15.19 33.25
2017-12-31 22.52 15.09 41.78
2017-09-30 12.56 14.99 32.34
2017-06-30 20.67 14.90 40.31
2017-03-31 30.87 14.80 49.02
2016-12-31 40.72 14.73 59.94
2016-09-30 52.07 0.00 56.29
2016-06-30 43.97 0.00 45.40
2016-03-31 53.75 0.00 61.20
2015-12-31 -5.15 5.44 4.78
2015-09-30 1.76 0.00 2.14
2014-12-31 0.53 0.00 0.78
2013-12-31 0.11 0.00 0.14
  • Eiger BioPharmaceuticals's level of debt (53.8%) compared to net worth is high (greater than 40%).
  • Unable to establish if Eiger BioPharmaceuticals's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Eiger BioPharmaceuticals has sufficient cash runway for 1.5 years based on current free cash flow.
  • Eiger BioPharmaceuticals has sufficient cash runway for 1.2 years if free cash flow continues to grow at historical rates of 32.7% each year.
X
Financial health checks
We assess Eiger BioPharmaceuticals's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Eiger BioPharmaceuticals has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

EIGR Dividends

 What is Eiger BioPharmaceuticals's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Eiger BioPharmaceuticals dividends. Estimated to be 0% next year.
If you bought $2,000 of Eiger BioPharmaceuticals shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Eiger BioPharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Eiger BioPharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGM:EIGR Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 65 Stocks 2.3%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 1949 Stocks 3%
United States of America Minimum Threshold Dividend Yield 10th Percentile 1.1%
United States of America Bottom 25% Dividend Yield 25th Percentile 2%
United States of America Top 25% Dividend Yield 75th Percentile 5.4%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGM:EIGR Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31
2021-12-31 0.00 1.00
2020-12-31 0.00 1.00
2020-03-28

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Eiger BioPharmaceuticals has not reported any payouts.
  • Unable to verify if Eiger BioPharmaceuticals's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Eiger BioPharmaceuticals's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Eiger BioPharmaceuticals has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Eiger BioPharmaceuticals's dividends in 3 years as they are not expected to pay a notable one for United States of America.
X
Income/ dividend checks
We assess Eiger BioPharmaceuticals's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Eiger BioPharmaceuticals afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Eiger BioPharmaceuticals has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

EIGR Management

 What is the CEO of Eiger BioPharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
David Cory
COMPENSATION $2,091,742
AGE 55
TENURE AS CEO 4 years
CEO Bio

Mr. David A. Cory, R.Ph, MBA, is Business Founder of Eiger Biopharmaceuticals, Inc. and has been its Chief Executive Officer and President since March 22, 2016. Mr. Cory served as the Chief Executive Officer of DiObex, Inc. since April 2007 until 2008. He served as the President and Chief Operating Officer of Prestwick Pharmaceuticals Inc., since August 2004 until 2006 and served as its Chief Commercial Officer from September 2003 to July 2004. At Prestwick Pharmaceuticals Inc. where he had been responsible for U.S. operations, creation of the Canadian commercial subsidiary. From February 2003 to September 2003, he served as the Chief Commercial Officer of CoTherix, Inc. where he was responsible for in-licensing the company’s lead product, Ventavis, from Schering AG. Mr. Cory was President and Chief Executive Officer of Private Eiger since 2009 until March 2016. Mr. Cory served as the Senior Vice President of Sales and Marketing of InterMune Inc. from January 2000 to 2003, where he played an executive role in the companies initial public offering and in-licensing of four products, built and led the U.S. commercial operation. Mr. Cory was Co-Founder and Acting Chief Commercial Officer at CoTherix in 2003.He has over 20 years of experience in large pharma, biotechnology and specialty pharma with an established track record of commercial success, financial transactions, business development and management experience. From November 1999 to January 2000, he served as a pharmaceutical industry consultant. From November 1988 to October 1999, Mr. Cory served in both sales and marketing management capacities, served as Commercial Director of U.S. marketing, where he was responsible for launching or managing over 10 products across oncology, Anesthesia, Critical Care, CNS, Infectious Disease and respiratory therapeutic areas, with Glaxo, Glaxo Smith Kline and Glaxo Wellcome. He began his career in sales with the Upjohn Company in 1987. He serves as a Director of Eiger Biopharmaceuticals, Inc. He served as an Executive Director of DiObex, Inc. since April 2007. Mr. Cory attended City College New York and University of Michigan and Graduated from the University of Michigan in 1950, receiving BA Degree in Economics. He attended the University of Cincinnati College of Pharmacy and the Fuqua School of Business at Duke University and is board certified in Pharmacy. He earned a B.S. in Pharmacy from the University of Cincinnati, College of Pharmacy and an M.B.A. from the University of Maryland University College.

CEO Compensation
  • David's compensation has increased whilst company is loss making.
  • David's remuneration is higher than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Eiger BioPharmaceuticals management team in years:

1.1
Average Tenure
55
Average Age
  • The average tenure for the Eiger BioPharmaceuticals management team is less than 2 years, this suggests a new team.
Management Team

David Cory

TITLE
Business Founder
COMPENSATION
$2M
AGE
55
TENURE
4 yrs

Jeffrey Glenn

TITLE
Founder
COMPENSATION
$110K
AGE
56
TENURE
4 yrs

Jim Shaffer

TITLE
Chief Business Officer
COMPENSATION
$949K
AGE
52
TENURE
4 yrs

Eldon Mayer

TITLE
Executive VP & Chief Commercial Officer
COMPENSATION
$349K
AGE
58
TENURE
0.2 yrs

Sri Ryali

TITLE
Chief Financial Officer
AGE
38
TENURE
1.3 yrs

Stephana Patton

TITLE
General Counsel
AGE
48
TENURE
1 yrs

Ingrid Choong

TITLE
Senior Vice President of Clinical Development
TENURE
0.2 yrs

Rich Franco

TITLE
Senior Vice President of Progeria Program
TENURE
0.9 yrs

Colin Hislop

TITLE
Senior Vice President of Clinical & Development Operations
AGE
61
Board of Directors Tenure

Average tenure and age of the Eiger BioPharmaceuticals board of directors in years:

2.8
Average Tenure
55
Average Age
  • The average tenure for the Eiger BioPharmaceuticals board of directors is less than 3 years, this suggests a new board.
Board of Directors

Tom Dietz

TITLE
Chairman
COMPENSATION
$136K
AGE
55
TENURE
4 yrs

David Cory

TITLE
Business Founder
COMPENSATION
$2M
AGE
55
TENURE
4 yrs

Jeffrey Glenn

TITLE
Founder
COMPENSATION
$110K
AGE
56
TENURE
4 yrs

Evan Loh

TITLE
Independent Director
COMPENSATION
$105K
AGE
60
TENURE
2.5 yrs

Tracey McLaughlin

TITLE
Scientific Advisor

Stanley Rockson

TITLE
Scientific Advisor

David Apelian

TITLE
Director
COMPENSATION
$2M
AGE
54
TENURE
2.8 yrs

Christine Murray

TITLE
Independent Director
AGE
58
TENURE
1.2 yrs

Amit Sachdev

TITLE
Independent Director
AGE
51
TENURE
0.9 yrs
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by Eiger BioPharmaceuticals individual insiders in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
17. Mar 20 Buy Jeffrey Glenn Individual 16. Mar 20 16. Mar 20 30,000 $5.03 $150,813
17. Mar 20 Buy Thomas Dietz Individual 16. Mar 20 16. Mar 20 1,000 $4.95 $4,950
13. Jan 20 Buy Thomas Dietz Individual 10. Jan 20 10. Jan 20 4,000 $13.94 $55,760
26. Apr 19 Buy David Cory Individual 25. Apr 19 25. Apr 19 343 $11.26 $3,862
23. Apr 19 Buy Thomas Dietz Individual 23. Apr 19 23. Apr 19 5,000 $11.10 $55,495
23. Apr 19 Buy Sriram Ryali Individual 22. Apr 19 22. Apr 19 1,250 $11.08 $13,853
23. Apr 19 Buy Thomas Dietz Individual 22. Apr 19 22. Apr 19 5,000 $11.05 $55,250
23. Apr 19 Buy Stephana Patton Individual 22. Apr 19 22. Apr 19 1,000 $11.03 $11,030
X
Management checks
We assess Eiger BioPharmaceuticals's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Eiger BioPharmaceuticals has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

EIGR News

Simply Wall St News

Those Who Purchased Eiger BioPharmaceuticals (NASDAQ:EIGR) Shares Three Years Ago Have A 42% Loss To Show For It

For many investors, the main point of stock picking is to generate higher returns than the overall market. … But if you try your hand at stock picking, your risk returning less than the market. … A Different Perspective The last twelve months weren't great for Eiger BioPharmaceuticals shares, which cost holders 0.7%, while the market was up about 7.0%.

Simply Wall St -

Who Has Been Buying Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Shares?

For example, a Harvard University study found that 'insider purchases earn abnormal returns of more than 6% per year.' See our latest analysis for Eiger BioPharmaceuticals The Last 12 Months Of Insider Transactions At Eiger BioPharmaceuticals In the last twelve months, the biggest single purchase by an insider was when Director Eldon Mayer bought US$208k worth of shares at a price of US$10.07 per share. … NasdaqGM:EIGR Recent Insider Trading, June 6th 2019 Eiger BioPharmaceuticals is not the only stock insiders are buying. … We would certainly prefer see higher levels of insider ownership but analysis of the insider transactions suggests that Eiger BioPharmaceuticals insiders are expecting a bright future.

Simply Wall St -

What Kind Of Shareholder Appears On The Eiger BioPharmaceuticals, Inc.'s (NASDAQ:EIGR) Shareholder Register?

Insiders often own a large chunk of younger, smaller, companies while huge companies tend to have institutions as shareholders. … We also tend to see lower insider ownership in companies that were previously publicly owned. … Eiger BioPharmaceuticals is not a large company by global standards.

Simply Wall St -

The Eiger BioPharmaceuticals (NASDAQ:EIGR) Share Price Is Up 38% And Shareholders Are Holding On

We'll need to follow Eiger BioPharmaceuticals for a while to get a better sense of its share price trend, since it hasn't been listed for particularly long. … With zero revenue generated over twelve months, we Eiger BioPharmaceuticals has proved its business plan yet. … It's a testament to the popularity of the business plan that the share price gained 38% in the last year, despite the weak balance sheet.

Simply Wall St -

How Many Insiders Bought Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Shares?

We often see insiders buying up shares in companies that perform well over the long term. … So shareholders might well want to know whether insiders have been buying or selling shares in Eiger BioPharmaceuticals, Inc. … Eiger BioPharmaceuticals Insider Transactions Over The Last Year.

Simply Wall St -

Who Really Owns Eiger BioPharmaceuticals Inc (NASDAQ:EIGR)?

A look at the shareholders of Eiger BioPharmaceuticals Inc (NASDAQ:EIGR) can tell us which group is most powerful. … Large companies usually have institutions as shareholders, and we usually see insiders owning shares in smaller companies. … With a market capitalization of US$158m, Eiger BioPharmaceuticals is a small cap stock, so it might not be well known by many institutional investors.

Simply Wall St -

Eiger BioPharmaceuticals Inc (NASDAQ:EIGR): When Will It Breakeven?

Eiger BioPharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare diseases in the United States and internationally. … With the latest financial year loss of -US$42.45m and a trailing-twelve month of -US$40.04m, the US$195.05m market-cap alleviates its loss by moving closer towards its target of breakeven. … Many investors are wondering the rate at which EIGR will turn a profit, with the big question being “when will the company breakeven?”

Simply Wall St -

Does Eiger BioPharmaceuticals Inc's (NASDAQ:EIGR) CEO Pay Reflect Performance?

View our latest analysis for Eiger BioPharmaceuticals What has EIGR's performance been like? … Therefore I will use earnings as a proxy of Cory's performance in the past year. … Usually I would look at market cap and earnings as a proxy for performance, however, EIGR's negative earnings lower the effectiveness of this method.

Simply Wall St -

Eiger BioPharmaceuticals Inc (NASDAQ:EIGR): What Are The Future Prospects?

The most recent earnings announcement Eiger BioPharmaceuticals Inc's (NASDAQ:EIGR) released in December 2017 suggested that losses became smaller relative to the prrior year's level - great news for investors Below, I've presented key growth figures on how market analysts predict Eiger BioPharmaceuticals's earnings growth outlook over the next few years and whether the future looks brighter. … View our latest analysis for Eiger BioPharmaceuticals Market analysts' consensus outlook for next year seems relatively subdued, with earnings continuing to flop around in the negative territory, arriving at -US$45.67M in 2019. … This means that, we can assume Eiger BioPharmaceuticals will grow its earnings by 11.82% every year for the next couple of years.

Simply Wall St -

When Will Eiger BioPharmaceuticals Inc (NASDAQ:EIGR) Turn A Profit?

In this article, I will touch on the expectations for EIGR’s growth and when analysts expect the company to become profitable. … Check out our latest analysis for Eiger BioPharmaceuticals EIGR is bordering on breakeven, according to analysts. … For a more comprehensive look at EIGR, take a look at EIGR’s company page on Simply Wall St.

Simply Wall St -

EIGR Company Info

Description

Eiger BioPharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare diseases in the United States and internationally. The company’s lead program is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trial for treating hepatitis delta virus (HDV) infection. Its product candidates also include Lambda, which targets type III IFN receptors; Lonafarnib for the treatment of progeria and progeroid laminopathies; Avexitide for treating post-bariatric hypoglycemia; and Ubenimex, an oral, small-molecule inhibitor of leukotriene A4 hydrolase for treating lymphedema. The company was founded in 2008 and is headquartered in Palo Alto, California.

Details
Name: Eiger BioPharmaceuticals, Inc.
EIGR
Exchange: NasdaqGM
Founded: 2008
$171,422,008
24,559,027
Website: http://www.eigerbio.com
Address: Eiger BioPharmaceuticals, Inc.
2155 Park Boulevard,
Palo Alto,
California, 94306,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM EIGR Common Stock Nasdaq Global Market US USD 23. Mar 2016
DB 72C1 Common Stock Deutsche Boerse AG DE EUR 23. Mar 2016
Number of employees
Current staff
Staff numbers
24
Eiger BioPharmaceuticals employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/03/28 03:56
End of day share price update: 2020/03/27 00:00
Last estimates confirmation: 2020/03/24
Last earnings filing: 2020/03/13
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.